

369

N-terminal peptide R-Leu-Gln-Arg-Ser-Ser-OH (II) of human beta-interferon as a hapten with a carrier in the presence of a hapten-carrier binding agent, to give a peptide-carrier complex. In (II) is H, H-Phe-, H-Leu-Gly-Phe-, H-Tyr-Asn-Leu-Leu-Gly-Phe- or H-Met-Ser-Tyr-Asn-Leu-Gly-Phe-. (I) is useful in obtaining human beta-interferon antibody in high specificity.

The peptide (II) is linked to a carrier in the presence of a hapten-carrier binding agent. Examples of the carrier are horse serum albumin, bovine serum albumin, rabbit serum albumin, human serum albumen, ovine serum albumin, horse serum globulin, bovine serum globulin, rabbit serum globulin, ovine hemoglobin, animal hemocyanine, a protein extract from Ascaris, polylysine, polyglutamic acid, lysine-glutamic acid copolymer and lysine-ornithine copolymer. As the hapten-carrier binding agent are mentioned aliphatic dialdehydes (e.g. glyoxal, malondialdehyde, glutaraldehyde, succinaldehyde, adipaldehyde), N,N'-o-phenylenedimaleimide, m-maleimidobenzoyl-N-hydroxysuccinimide ester, N,N-dicyclohexyl carbodiimide, N-ethyl-N'-dimethylaminocarbodiimide, 1-ethyl-3-diisopropylamino carbodiimide, 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide, etc. The reaction is effected in water or a buffer at 0-40 deg.C. within a pH range of 7-10 for 1-24

? S PN=JP 58225028

S7 1 PN=JP 58225028

? T 7/3,AB/1

7/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

003888691

WPI Acc No: 1984-034233/*198406*

XRAM Acc No: C84-014549

Human alpha-interferon antibody prepn. - by injecting alpha-interferon antigen into animal

Patent Assignee: OTSUKA PHARM CO LTD (SAKA)

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 58225028	A	19831227	JP 82110470	A	19820625	198406 B
JP 92053880	B	19920827	JP 82110470	A	19820625	199239

Priority Applications (No Type Date): JP 82110470 A 19820625

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 58225028	A		14		
JP 92053880	B		92	C07K-015/14	Based on patent JP 58225028

Abstract (Basic): JP 58225028 A

Human alpha-interferon antigen comprising complex of C-terminal peptide of human lymphoblastoid interferon of formula R-Ser-Leu-Ser-Thr-Asn-Gln-Clu -Ser-Leu-Arg-Ser-Lys-Glu-OH (where R is H or H-Tyr-) or its derivative thereof, and carrier, is dosed to mammal, and the formed antigen is taken out.

Antibody is specifically reactive to human alpha-interferons (I), and is used for determin. of (I) by radioimmunoassay or enzyme-immunoassay or for purificn. of (I) by affinity-chromatography

(I) antigen is prepd. by reaction of 1 of the peptides (as hapten) and carrier in the presence of hapten-carrier binding agent. Carriers may be natural and synthetic proteins, e.g. animal serum albumin (human serum albumin, bovine serum albumin), animal serum globulin, animal thyroglobulin, animal hemoglobin, lysine-glutamic acid copolymer, polylysine, polyglutamic acid, etc.. Binding agents are, e.g. aliphatic dialdehydes (glyoxal, malondialdehyde), dimaleimides (N,N'-o-phenylene-dimaleimide), maleimide-carboxyl -N-hydroxysuccinimide-esters, carbodiimides, etc..

? S PN=JP 61073665

S8 1 PN=JP 61073665

? T 8/3,AB/1

8/3,AB/1

DIALOG(R) File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

004632176

WPI Acc No: 1986-135519/*198621*

XRAM Acc No: C86-058161

XRPX Acc No: N86-100158

Protecting wounds by artificial membrane - by applying soln. contg.

anionic polymer and calcium salt soln. contg. cationic polymer to wound

Patent Assignee: KUMABE K (KUMA-I)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 61073665	A	19860415	JP 84195767	A	19840920	198621 B

Priority Applications (No Type Date): JP 84195767 A 19840920

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 61073665	A		4		

Abstract (Basic): JP 61073665 A

First soln. is prepd. by heating and sterilising at least one anionic macromolecular material aq. soln.. The second soln. is prepd. by adding a calcium salt aq. soln. to at least one cationic macromolecular material aq. solution and by heating and sterilising the calcium salt aq. soln.-contg. cationic macromolecular material aq. soln.. The first soln. and the second soln. are applied to a wound and the surrounding area to form a membrane.

The first soln. is a 0.1-10.0% anionic macromolecular aq. soln.. The second soln. is a soln. prepd. to pH 5 by adding a 5-10.0 % Ca salt aq. soln. to a 0.1-5.0 % cationic macromolecular aq. soln. The anionic macromolecular material is that selected from xanthan gum, alginic acid, and galacturonic acid. The cationic macromolecular material is that selected from chitosan, polylysine and copolymer of dihydroxyethylaminopropyl and glutamic acid. The first soln. and the second soln. are sprayed at the wound and the surrounding area.

USE/ADVANTAGE - The membrane developed has good adhesion to a skin, resulting in protecting the wound and eliminating the need for applying a gauze to the wound.